Trial Profile
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Gosuranemab (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Adverse reactions
- Acronyms TANGO
- Sponsors Biogen
- 08 Mar 2024 This trial has been completed in Italy according to European Clinical Trials Database record.
- 04 Aug 2022 Results of post hoc exploratory analysis, assessing the feasibility and validity of assessing 18F-MK-6240 tau PET positivity, presented at the Alzheimer's Association International Conference 2022
- 03 Nov 2021 According to a Biogen media release , data from this trial will be presented at the upcoming annual Clinical Trials on Alzheimers Disease conference (CTAD)